Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia.
暂无分享,去创建一个
R. Warrell | A. F. Stewart | B. Gertz | S. Nussbaum | S. Averbuch | R. Rude | M. Stepanavage | J. Bilezikian | J. Glusman | J. Sacco
[1] J. Bilezikian. Management of acute hypercalcemia. , 1992, The New England journal of medicine.
[2] R. Rizzoli,et al. Effect of a single infusion of alendronate in malignant hypercalcaemia: Dose dependency and comparison with clodronate , 1992, International journal of cancer.
[3] P. Delmas,et al. Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia. , 1992, The Journal of clinical endocrinology and metabolism.
[4] G. Rodan,et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. , 1991, The Journal of clinical investigation.
[5] A. Howell,et al. Parathyroid hormone-related protein(50-69) and response to pamidronate therapy for tumour-induced hypercalcaemia. , 1991, European journal of cancer.
[6] B. Mitlak,et al. Parathyroid Hormone-Related Peptide Mediates Hypercalcemia in an Islet Cell Tumor of the Pancreas , 1991, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[7] M. Cecchini,et al. Bisphosphonates in vitro specifically inhibit, among the hematopoietic series, the development of the mouse mononuclear phagocyte lineage , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[8] D. Thiebaud,et al. Response to retreatment of malignant hypercalcemia with the bisphosphonate AHPrBP (APD): Respective role of kidney and bone , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[9] J. Sculier,et al. Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor‐associated hypercalcemia: A randomized comparison between a 3‐day treatment and single 24‐hour infusions , 1989, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[10] D. Heath,et al. Comparison of different dose regimes of aminohydroxypropylidene-1,1-bisphosphonate (APD) in hypercalcaemia of malignancy. , 1989, British journal of clinical pharmacology.
[11] R. Kefford,et al. RENAL PHOSPHATE THRESHOLD AND RESPONSE TO PAMIDRONATE IN HUMORAL HYPERCALCAEMIA OF MALIGNANCY , 1989, The Lancet.
[12] R. Cowan,et al. Clinical experience with aminohydroxypropylidene bisphosphonate (APD) in the management of cancer-associated hypercalcaemia. , 1988, The Quarterly journal of medicine.
[13] R. Warrell. Questions about clinical trials in hypercalcemia. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] S. Adami,et al. The use of dichloromethylene bisphosphonate and aminobutane bisphosphonate in hypercalcemia of malignancy. , 1987, Bone and mineral.
[15] J. Neijt,et al. Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride. , 1987, The American journal of medicine.
[16] L. Mosekilde,et al. Etidronate disodium for treating hypercalcaemia of malignancy: a double blind, placebo‐controlled study , 1986, European journal of clinical investigation.
[17] S. Ralston,et al. COMPARISON OF AMINOHYDROXYPROPYLIDENE DIPHOSPHONATE, MITHRAMYCIN, AND CORTICOSTEROIDSICALCITONIN IN TREATMENT OF CANCER-ASSOCIATED HYPERCALCAEMIA , 1985, The Lancet.
[18] E. Siris,et al. Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate. , 1981, Annals of internal medicine.
[19] P. Ritch,et al. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] R. Peyron,et al. TREATMENT OF HYPERCALCEMIA OF MALIGNANCY WITH INTRAVENOUS AMINOHYDROXYPROPYLIDENE BISPHOSPHONATE , 1991 .
[21] R. Rizzoli,et al. Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate. , 1988, Bone.